Pharmala Biotech Holdings Inc.
MDMA
CNSX
| 02/28/2025 | 11/30/2024 | 08/31/2024 | 05/31/2024 | 02/29/2024 | |
|---|---|---|---|---|---|
| Net Income | -1.38M | -981.00K | -606.00K | -502.50K | -448.90K |
| Total Depreciation and Amortization | 22.70K | 25.30K | 27.10K | -4.80K | 4.60K |
| Total Amortization of Deferred Charges | 47.40K | 36.20K | 24.50K | 49.60K | 38.30K |
| Total Other Non-Cash Items | 1.04M | 699.50K | 606.80K | 303.30K | 36.80K |
| Change in Net Operating Assets | -251.00K | -201.20K | -289.40K | -103.60K | 45.40K |
| Cash from Operations | -518.50K | -421.10K | -236.90K | -257.60K | -323.50K |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -953.50K | -143.10K | -166.70K | -334.90K | -353.40K |
| Cash from Investing | -953.50K | -143.10K | -166.70K | -334.90K | -353.40K |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 2.39M | 797.50K | 825.00K | 825.00K | 220.20K |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -84.00K | -52.90K | -52.90K | -27.00K | -- |
| Cash from Financing | 1.64M | 546.20K | 566.60K | 585.50K | 162.00K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 164.60K | -17.90K | 163.00K | -7.00K | -514.90K |